Refractive Solutions · Surgeon Series
Not everyone qualifies
for LASIK. The alternative
is a lens, not a laser.
LASIK reshapes the cornea by removing tissue. A phakic IOL — the ICL — adds a lens instead and leaves the cornea untouched. One is subtractive and permanent; the other is additive and reversible. Here is the vault math, the candidacy criteria, and the evidence behind choosing between them.
window
can correct
removed
Section 01 — Two Philosophies
Subtract the cornea,
or add a lens.
Not the same decision.
Patients arrive asking "LASIK or ICL?" as if it were a preference, like choosing a lens coating. It usually is not. For a meaningful share of people who want to be free of glasses, LASIK is not on the table at all — not because it would work poorly, but because the tissue math does not allow it safely. Understanding why requires separating what each procedure actually does.
LASIK (laser-assisted in situ keratomileusis) cuts a thin corneal flap, lifts it, and uses an excimer laser to ablate stromal tissue underneath, reshaping the curvature that focuses light onto the retina. Every dioptre of myopia corrected consumes a predictable depth of tissue. The cornea only has so much to give, and once it is removed it does not come back.
An implantable collamer lens (ICL, sold as the Visian ICL / EVO ICL) is a different category of procedure entirely: a soft, biocompatible phakic intraocular lens is folded, inserted through a small incision, and unfolded into the posterior chamber — behind the iris, in front of the eye's own natural crystalline lens. Nothing is removed. The cornea's shape and thickness are exactly what they were before surgery.
LASIK is subtractive and permanent: it reshapes the cornea by removing tissue, so it is limited by how much stroma a given cornea can safely lose, and the effect cannot be undone. An ICL is additive and reversible: it corrects refractive error by placing a lens inside the eye without touching the cornea at all, so it is not limited by corneal thickness and can be explanted or exchanged later. The clinical consequence is candidacy, not preference — thin corneas, very high myopia, and borderline topography rule out LASIK on safety grounds well before an ICL becomes the fallback option rather than the first choice.
Section 02 — Interactive
The number that decides
everything: vault.
Once an ICL is the chosen route, the single most important measurement is vault — the gap between the back of the implanted lens and the front of the eye's own natural lens. Adjust the anterior chamber depth below and watch what happens to that gap, and why the target window is narrower than most patients expect.
A vault that is too low lets the ICL contact the natural lens directly, and mechanical contact accelerates anterior subcapsular cataract formation — the complication that dogged early-generation phakic IOLs. A vault that is too high pushes the peripheral iris forward, narrowing the drainage angle between iris and cornea and raising the risk of pigment dispersion syndrome and secondary angle-closure glaucoma. The accepted safe range, drawn from anterior segment OCT and ultrasound biomicroscopy studies, sits between roughly 250 and 750 microns — about one to three corneal thicknesses. Getting there is a sizing exercise done before surgery, combining anterior chamber depth, white-to-white corneal diameter and sulcus-to-sulcus distance, not something adjusted intraoperatively by feel.
Section 03 — Why LASIK Runs Out of Tissue
The 250-micron rule
that disqualifies
more people than you think.
LASIK safety rests on a single, unforgiving number: the residual stromal bed, or RSB — the amount of untouched stroma left underneath the flap after ablation. Cut it too thin and the cornea loses the structural rigidity to resist the eye's internal pressure, and it starts to bulge. That bulging, progressive and irreversible, is corneal ectasia.
The arithmetic is straightforward and unforgiving. A typical flap consumes roughly 100 to 120 microns. Each dioptre of myopia corrected consumes roughly 12 to 15 microns of additional ablation depth, scaled by optical zone. The accepted minimum RSB is 250 microns, though many surgeons work to a more conservative 300-micron floor. Run the numbers on a cornea of average thickness (around 540 microns centrally) correcting −8D, and the RSB can already be uncomfortably close to the line before any safety margin for a thinner-than-average cornea, an eccentric ablation, or an unrecognized subclinical ectasia risk.
| Preoperative factor | Effect on LASIK candidacy | ICL affected? |
|---|---|---|
| Thin central cornea (<500µm) | Reduces available RSB; often disqualifies high-power correction | No — cornea untouched |
| High myopia (beyond −8 to −10D) | Ablation depth required approaches or exceeds safe RSB on many corneas | No — corrects to −18/−20D |
| Forme fruste keratoconus / suspicious topography | Absolute contraindication — ablation can trigger overt ectasia | Generally no, subject to full anterior segment work-up |
| Chronic severe dry eye | Flap creation and ablation both worsen dry eye; often deferred or excluded | Minimal effect — no flap, no corneal nerve transection |
| Shallow anterior chamber | Not a LASIK factor | Yes — directly limits safe vault and may exclude ICL |
| Low endothelial cell count | Not a direct LASIK factor | Yes — ICL requires adequate endothelial reserve; monitored postoperatively |
Randleman and colleagues formalised this into a scoring system — the Ectasia Risk Score Factor, published in Ophthalmology in 2008 — combining topography pattern, RSB, age, preoperative corneal thickness and manifest refraction into a single risk stratification. Corneas scoring in the high-risk band are steered away from LASIK regardless of how the individual numbers look in isolation. This is precisely the population where a phakic IOL becomes the primary option rather than a fallback: the cornea is not being asked to give up anything.
Section 04 — How the ICL Sits
Behind the iris,
in front of
the eye's own lens.
A posterior chamber phakic IOL occupies the sulcus — the shallow groove behind the iris and in front of the natural crystalline lens — a space the eye is not normally using for anything. The lens is made of Collamer, a proprietary collagen copolymer chosen for biocompatibility and a UV-blocking chromophore built into the material.
Early phakic IOL designs had no opening in the lens body, which meant aqueous humour flowing from behind the iris to the front of the eye had to route around the lens edge. That could restrict flow enough to require a preoperative laser peripheral iridotomy to prevent pupillary block. The current-generation EVO/EVO+ ICL adds a small central port — a 0.36mm aperture through the middle of the optic — that lets aqueous pass directly through the lens. This removed the need for a separate iridotomy procedure in most cases and is credited with more physiological aqueous circulation, though it did not eliminate cataract or glaucoma risk outright — those still track primarily with vault.
Section 05 — The Evidence
What the comparative
trials actually show.
Preference aside, a genuine literature exists comparing ICL and LASIK outcomes head-to-head in patients who could technically have either. It converges on a consistent pattern: comparable visual acuity outcomes at moderate corrections, with the ICL group showing an edge on contrast sensitivity and aberration profile as the correction gets larger.
Illustrative visualisation of the direction and rough magnitude reported across comparative series (Igarashi et al., and related literature) — see References for source studies. Not pooled meta-analytic effect sizes.
Igarashi and colleagues published two of the more widely cited comparative studies: a 2009 report in the American Journal of Ophthalmology comparing visual performance after posterior chamber phakic IOL implantation against LASIK for low-to-moderate myopia, and a longer-term 2014 follow-up study of phakic IOL outcomes at eight years. Across this and related work, the recurring finding is that ICL eyes tend to show less induced higher-order aberration and better contrast sensitivity than LASIK eyes at equivalent correction, with the gap widening as the corrected diopter range increases — consistent with the structural explanation that ablating a larger, deeper optical zone on the cornea has more effect on aberration than adding a lens power inside the eye does.
The original FDA clinical trial of the Visian ICL, published by Sanders, Doney and Poco in Ophthalmology in 2003, reported high rates of patient satisfaction and an efficacy index near 1.0 for moderate-to-high myopia correction, establishing the safety and efficacy baseline that later design iterations, including the ported EVO models, have built on. Packer's 2018 review of the EVO ICL's clinical literature in Clinical Ophthalmology summarised the accumulated post-approval data on the ported design specifically, including its effect on cataract and iridotomy rates relative to earlier non-ported models.
correction limit
procedure time
removed
Section 06 — Risk, Honestly Stated
Both procedures
carry real risk.
They are different risks.
A guide that only lists LASIK's downsides and skips the ICL's is not honest, and it is not useful to a patient trying to choose. Both carry a real, documented complication profile. The difference is in kind, not in one being risk-free.
| Risk | LASIK | ICL |
|---|---|---|
| Ectasia | Real, dose- and screening-dependent; irreversible once it occurs | Not applicable — cornea untouched |
| Dry eye | Common in the months after surgery from corneal nerve transection during flap creation; usually improves, occasionally chronic | Minimal direct effect — no flap, no corneal incision of comparable size |
| Cataract | Not a mechanism of LASIK itself | Documented risk with low/negative vault or oversized lens; lower with modern ported designs and accurate sizing |
| Glaucoma / pigment dispersion | Not a direct LASIK mechanism | Documented risk with excessive vault narrowing the drainage angle |
| Endothelial cell loss | Not a direct LASIK mechanism | Requires baseline endothelial count and periodic monitoring; a reason very low endothelial reserve can exclude ICL |
| Flap complications | Displacement, striae, epithelial ingrowth — procedure-specific to the flap step | Not applicable — no flap created |
| Reversibility of the intervention itself | None — ablated tissue does not regenerate | High — lens can be explanted or exchanged |
Section 07 — Where the Decision Actually Gets Made
The work-up decides it,
not the patient's preference.
In practice the choice is rarely a genuine toss-up. A thorough preoperative work-up — corneal topography, pachymetry, anterior chamber depth and angle assessment, endothelial cell count, and a careful refraction and dry eye history — tends to point clearly at one option or rule the other out entirely before cost or convenience enters the conversation.
A patient with −13D of myopia and a central corneal thickness of 500 microns — entirely unremarkable, not thin by population standards — is nonetheless a poor LASIK candidate at that correction. The ablation depth required to treat −13D would consume enough stroma to push the residual stromal bed close to or under the accepted safety floor even before applying a conservative margin. The myopia itself, not corneal quality, is the disqualifying variable. An ICL corrects the same −13D without touching the cornea at all, which is precisely the population the FDA trial and subsequent literature were built around: high myopes for whom LASIK's tissue math simply does not close.
The inverse case is just as common: a patient with modest myopia, a normal cornea, excellent tear film and no topographic concerns is usually a straightforward LASIK candidate, and an ICL — an intraocular procedure with its own monitoring requirements — would be doing more surgery than the correction requires. Matching the tool to the anatomy, not the anatomy to a preferred tool, is the entire discipline.
Section 08 — The Agaaz Range
What sits in the tray
during the implantation.
Agaaz Ophthalmics does not manufacture phakic IOL platforms, but the intraocular case built around a phakic lens implantation — anterior chamber protection during insertion and intracameral infection prophylaxis at close — is the same clinical territory Agaaz supplies for cataract and other intraocular surgery. GMP-manufactured, and specified below by what they are, not how they are positioned.
These consumables are part of the same intraocular solutions range covered in the cohesive vs dispersive OVD guide. View the complete portfolio →
Section 09 — FAQ
Frequently asked questions
about ICL vs LASIK.
LASIK is subtractive: an excimer laser reshapes the cornea by removing tissue to change how light bends. An ICL (implantable collamer lens) is additive: a soft phakic lens is placed inside the eye, in front of the natural lens and behind the iris, without removing any corneal tissue at all. LASIK permanently alters the cornea; an ICL can be removed or exchanged, and the cornea underneath is never touched.
The most common reason is corneal thickness. LASIK must leave a residual stromal bed (RSB) of at least 250 microns after the flap and ablation, and higher myopia needs deeper ablation, so thin corneas and high prescriptions run out of safe tissue to remove. Other disqualifiers include topography suspicious for keratoconus, chronic severe dry eye, and a stable refraction that is simply too high — corrections beyond about −8 to −10D on a thin cornea carry a much higher ectasia risk.
Vault is the gap between the back of the ICL and the front of the patient's natural crystalline lens, measured in microns. The accepted safe window is roughly 250 to 750 microns. Too low a vault lets the ICL rub against the natural lens, accelerating cataract formation. Too high a vault pushes the iris forward, narrowing the drainage angle and raising the risk of pigment dispersion and secondary glaucoma. Vault is set at the sizing stage using anterior chamber depth, white-to-white and sulcus-to-sulcus measurements, not guessed at during surgery.
Yes, in a way LASIK is not. An ICL is a removable implant sitting inside the eye rather than a permanent reshaping of the cornea. It can be explanted or exchanged for a different power if the prescription changes materially, and the underlying corneal anatomy is unaffected either way. LASIK's tissue removal is permanent regardless of outcome.
Older-generation ICL models without a central port had a measurable rate of anterior subcapsular cataract, linked mainly to a low or negative vault bringing the lens into contact with the natural lens, and to oversized lenses. The EVO/EVO+ ICL's central port improves aqueous circulation and, combined with more accurate modern sizing protocols, has been associated with materially lower cataract rates in longer follow-up series. It is not zero, which is why sizing accuracy and postoperative vault monitoring both still matter.
Several comparative series studying moderate to high myopia have reported better contrast sensitivity and fewer higher-order aberrations after ICL implantation than after LASIK of an equivalent correction, particularly at higher diopter ranges. The likely reason is structural: LASIK's ablation profile flattens the central cornea and can increase spherical aberration, especially at larger optical zones and higher corrections, while the ICL corrects power without altering corneal curvature at all.
Commercially available ICL platforms correct myopia across a wide range, commonly cited up to roughly −18 to −20D of spherical myopia and up to about −6D of cylinder in toric versions, which is well beyond what LASIK can safely address on most corneas. This is the single biggest reason ICLs exist as a category: extreme myopes are frequently LASIK-ineligible by tissue math alone, independent of corneal thickness.
References & Evidence Base
Peer-reviewed
citations.
Continue Reading
Related guides
from Beyond Vision.
Start writing here...
ICL vs LASIK: The Phakic Lens Alternative When Your Cornea Says No (2026 Guide)